Attention GBP traders, UK stock investors, and anyone following the British economy – brace yourselves. This week could be the most decisive for the pound in 2025.
📉 Expected Rate Cut: The Bank of England is widely anticipated to lower the Official Bank Rate from 4.25% to 4.00% – a 0.25% drop – this Thursday at 11:00 a.m. GMT.
💬 The announcement will coincide with a press briefing revealing the latest monetary policy outlook.
⚠️ A rate cut could send the pound sliding against other major currencies, creating both opportunities and risks for traders.
📊 Be ready – market volatility is coming.
Sign Up Now➡️ https://tlt.ink/exness
📉 Expected Rate Cut: The Bank of England is widely anticipated to lower the Official Bank Rate from 4.25% to 4.00% – a 0.25% drop – this Thursday at 11:00 a.m. GMT.
💬 The announcement will coincide with a press briefing revealing the latest monetary policy outlook.
⚠️ A rate cut could send the pound sliding against other major currencies, creating both opportunities and risks for traders.
📊 Be ready – market volatility is coming.
Sign Up Now
Please open Telegram to view this post
VIEW IN TELEGRAM
OPEC+ has announced a production boost of 547,000 barrels per day.
And here’s where the law of supply and demand comes into play:
📈 More Production → More Supply → 📉 Lower Prices
This surge in output means more oil flooding the global market, which could put long-term downward pressure on prices.
💡 Traders, keep your eyes on the charts—this could shape the next big move in crude oil.
And here’s where the law of supply and demand comes into play:
📈 More Production → More Supply → 📉 Lower Prices
This surge in output means more oil flooding the global market, which could put long-term downward pressure on prices.
💡 Traders, keep your eyes on the charts—this could shape the next big move in crude oil.
ETHUSD, daily chart
ETHUSD rebounded above EMA21 and the ascending channel's breakout zone. The price remains in an uptrend, with higher swings and a widening gap between the bullish EMAs.
If ETHUSD sustains its bullish momentum, the price could approach the psychological resistance at 4000.
Conversely, a break below the support at 3300 and returning within the channel could prompt a deeper retracement toward the following support at 2850.
ETHUSD rebounded above EMA21 and the ascending channel's breakout zone. The price remains in an uptrend, with higher swings and a widening gap between the bullish EMAs.
If ETHUSD sustains its bullish momentum, the price could approach the psychological resistance at 4000.
Conversely, a break below the support at 3300 and returning within the channel could prompt a deeper retracement toward the following support at 2850.
Start trading with the XM App and trade on-the-go anytime, anywhere. 💪🎯
📱 From gold to forex and over 1400 instruments, the XM App offers a superior trading environment that puts traders in the best position to profit.
Download XM App now : https://tlt.ink/xmbro
#XM #XMIndia #XMApp #ForexTrading #OnlineTrading #ForexApp
📱 From gold to forex and over 1400 instruments, the XM App offers a superior trading environment that puts traders in the best position to profit.
Download XM App now : https://tlt.ink/xmbro
#XM #XMIndia #XMApp #ForexTrading #OnlineTrading #ForexApp
ETHUSD, daily chart
ETHUSD rebounded above EMA21 and the ascending channel's breakout zone. The price remains in an uptrend, with higher swings and a widening gap between the bullish EMAs.
If ETHUSD sustains its bullish momentum, the price could approach the psychological resistance at 4000.
Conversely, a break below the support at 3300 and returning within the channel could prompt a deeper retracement toward the following support at 2850.
ETHUSD rebounded above EMA21 and the ascending channel's breakout zone. The price remains in an uptrend, with higher swings and a widening gap between the bullish EMAs.
If ETHUSD sustains its bullish momentum, the price could approach the psychological resistance at 4000.
Conversely, a break below the support at 3300 and returning within the channel could prompt a deeper retracement toward the following support at 2850.
Traders move fast. So should your money.
With Exness, over 98% of withdrawals are instant, processed with no manual intervention.
No waiting. No hidden fees. Just seamless access to your capital.
Trade with the broker that doesn't keep you waiting.
#BorntoTrade #Exness
With Exness, over 98% of withdrawals are instant, processed with no manual intervention.
No waiting. No hidden fees. Just seamless access to your capital.
Trade with the broker that doesn't keep you waiting.
#BorntoTrade #Exness
🍽️ What’s the company behind the weight-loss drug Mounjaro™ that’s got investors and traders hungry for more?
Eli Lilly and Company—often referred to as Lilly—is the pharmaceutical giant behind Mounjaro™ and Zepbound™ (tirzepatide), a weight-loss and diabetes treatment that’s storming the markets. Since early 2020, Lilly’s stock has soared over 300%. When Mounjaro was first approved in May 2022, shares were trading at 284.14 USD. Today, they're hovering near 640.00 USD.
According to MarketWatch, Eli Lilly’s stock is down approximately 17% in 2025 (YTD), but the long-term bullish outlook remains strong, driven by the surging demand in the obesity drug market. From a fundamentals perspective, Lilly now holds a 685 billion USD market cap. Over the past 12 months, it has generated 49 billion USD in revenue, with 20 billion USD in operating profit and 11 billion USD in net income.
📈📉 Pharma is feasting on the weight-loss wave. Are you buying, selling, or waiting for the next course?
Sign Up Now➡️ https://tlt.ink/exness
Eli Lilly and Company—often referred to as Lilly—is the pharmaceutical giant behind Mounjaro™ and Zepbound™ (tirzepatide), a weight-loss and diabetes treatment that’s storming the markets. Since early 2020, Lilly’s stock has soared over 300%. When Mounjaro was first approved in May 2022, shares were trading at 284.14 USD. Today, they're hovering near 640.00 USD.
According to MarketWatch, Eli Lilly’s stock is down approximately 17% in 2025 (YTD), but the long-term bullish outlook remains strong, driven by the surging demand in the obesity drug market. From a fundamentals perspective, Lilly now holds a 685 billion USD market cap. Over the past 12 months, it has generated 49 billion USD in revenue, with 20 billion USD in operating profit and 11 billion USD in net income.
📈📉 Pharma is feasting on the weight-loss wave. Are you buying, selling, or waiting for the next course?
Sign Up Now
Please open Telegram to view this post
VIEW IN TELEGRAM